Gilead Sciences (GILD) Stock Highlights

83.32 | +0.62%

2024-09-16 19:23:26

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gileads acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gileads exposure to cell therapy and noncell therapy in oncology.

Statistics

Range Today

82.53 83.32

Volume Today 4.58M

Range 1 Year

62.07 87.87

Volume 1 Year 1.7B

Range 3 Year

57.17 89.74

Volume 3 Year 5.39B

Range 10 Year

56.56 123.37

Volume 10 Year 22.78B

Highlights

Market Capitalization 103.1B (large)

Floating Shares 1.24B

Current Price 83.32

Price To Earnings 99.94

Price To Revenue 4.41

Price To Book 5.64

Earnings Per Share 0.82

Dividend Yield 3.7%

Dividend Per Share 3.08

Payout Ratio 370.73%

Performance

Latest +0.62%

1 Month +12.69%

3 Months +28.68%

6 Months +13.07%

1 Year +9.83%

3 Years +16.04%

5 Years +25.69%

10 Years -16.55%

Benchmarks

Market Capitalization

10 / 14

Gross Profits

9 / 14

Total Revenue

9 / 14

Total Rank

6 / 14

Free Cashflow

6 / 14

Performance 5 years

8 / 14

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.